Your browser doesn't support javascript.
loading
A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis.
Collongues, Nicolas; Becker, Guillaume; Jolivel, Valérie; Ayme-Dietrich, Estelle; de Seze, Jérôme; Binamé, Fabien; Patte-Mensah, Christine; Monassier, Laurent; Mensah-Nyagan, Ayikoé Guy.
Affiliation
  • Collongues N; Department of Neurology, University Hospital of Strasbourg, Strasbourg, France. Nicolas.collongues@chru-strasbourg.fr.
  • Becker G; Center for Clinical Investigation, INSERM U1434, Strasbourg, France. Nicolas.collongues@chru-strasbourg.fr.
  • Jolivel V; Biopathology of Myelin, Neuroprotection and Therapeutic Strategy, INSERM U1119, Strasbourg, France. Nicolas.collongues@chru-strasbourg.fr.
  • Ayme-Dietrich E; University Department of Pharmacology, Addictology, Toxicology and Therapeutic, Strasbourg University, Strasbourg, France. Nicolas.collongues@chru-strasbourg.fr.
  • de Seze J; University Department of Pharmacology, Addictology, Toxicology and Therapeutic, Strasbourg University, Strasbourg, France.
  • Binamé F; NeuroCardiovascular Pharmacology and Toxicology Laboratory, UR7296, University Hospital of Strasbourg, Strasbourg, France.
  • Patte-Mensah C; Biopathology of Myelin, Neuroprotection and Therapeutic Strategy, INSERM U1119, Strasbourg, France.
  • Monassier L; University Department of Pharmacology, Addictology, Toxicology and Therapeutic, Strasbourg University, Strasbourg, France.
  • Mensah-Nyagan AG; NeuroCardiovascular Pharmacology and Toxicology Laboratory, UR7296, University Hospital of Strasbourg, Strasbourg, France.
Neurol Ther ; 11(3): 981-1042, 2022 Sep.
Article in En | MEDLINE | ID: mdl-35610531
ABSTRACT
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) resulting in demyelination and neurodegeneration. The therapeutic strategy is now largely based on reducing inflammation with immunosuppressive drugs. Unfortunately, when disease progression is observed, no drug offers neuroprotection apart from its anti-inflammatory effect. In this review, we explore current knowledge on the assessment of neurodegeneration in MS and look at putative targets that might prove useful in protecting the axon from degeneration. Among them, Bruton's tyrosine kinase inhibitors, anti-apoptotic and antioxidant agents, sex hormones, statins, channel blockers, growth factors, and molecules preventing glutamate excitotoxicity have already been studied. Some of them have reached phase III clinical trials and carry a great message of hope for our patients with MS.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Neurol Ther Year: 2022 Document type: Article Affiliation country: France

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Neurol Ther Year: 2022 Document type: Article Affiliation country: France